Description
Typical and atypical Alzheimer Disease: salivary tau biomarkers, therapy with neuromodulation, and disease subtypes.
Amendment chain · 1 entry
Each notch is one published row for this agreement: #0 is the original (placed at its start date) and each later notch is an amendment (placed at its amendment date). The height is the agreement's total value as of that row — the source column is cumulative, not a change amount — so the line reads as the commitment over time and the right-most notch is the current commitment shown in the header.
- #02015-07-01$1,695,053
| Row | Date | Total value as of row | Change vs previous | Description on this row |
|---|---|---|---|---|
| #0 original | 2015-07-01(start date) | $1,695,053 | — | Typical and atypical Alzheimer Disease: salivary tau biomarkers, therapy with neuromodulation, and disease sub… |
Related records · 3
Records are related by an explicit link in the data, stated for each group below — never by text similarity. Values are each agreement's current commitment (latest amendment).
Other current agreements for the same recipient (exact legal name match; no business number on file)
| Ref | Department · program | Current value | FY |
|---|---|---|---|
| 236-2024-2025-Q1-00280 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada · Research in Priority Areas Research in Priority Areas | $20,600,000 | FY2025 |
| 236-2019-2020-Q1-00523 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada · Research in Priority Areas | $31,625,000 | FY2020 |
| 236-2016-2017-Q2-00895 | Canadian Institutes of Health Research | Instituts de recherche en santé du Canada | $4,750,000 | FY2017 |
Cite as: Glassbox record view · Federal grants & contributions · 236-2015-2016-Q2-00621 · retrieved 2026-11-12.